Why is Marvell Technology stock rallying today?

Marvell Technology stock climbed 3.5% in pre-open trading today, staging a partial recovery after the chip designer’s shares were hammered by investor anxiety surrounding its reported pursuit of laser and optical components maker Lumentum Holdings in a potential all-stock transaction valued at approximately $83 billion. Reports first emerged in late October that the two companies had largely agreed on valuation and that a formal announcement could come as soon as this week, sending Marvell sharply lower on dilution fears.

The rebound reflects a reassessment of the deal’s strategic merits after analysts pushed back against the initial sell-off. Rosenblatt maintained its Buy rating and $300 price target, noting that Marvell has historically created value through scale advantages in silicon and the monetization of acquired intellectual property across a broader customer and product base.

Separately, B. Riley named Lumentum its top AI optics pick, highlighting its sold-out capacity through 2029 and the ongoing acquisition discussions — commentary that implicitly validated Marvell’s rationale for pursuing the deal. The strategic logic centers on Marvell gaining direct control over optical technology and manufacturing capacity critical to AI data center infrastructure, building on its earlier acquisition of photonics startup Celestial AI.

The broader market provided a constructive backdrop, with the NASDAQ gaining +0.9% and the S&P 500 adding +0.5%, while pre-market semiconductor stocks rose broadly — Arm, Micron, Lam Research, and AMD all posted gains alongside MRVL. This sector-wide lift helped amplify the bounce in Marvell shares, which had been among the hardest-hit chip names over the prior week.

Taken together, today’s move reflects a combination of dip-buying after an outsized deal-driven correction, renewed analyst conviction in Marvell’s M&A strategy, and a favorable macro and sector backdrop — though the stock still trades well below its 52-week high of $329.88, underscoring that deal uncertainty continues to weigh on the longer-term valuation picture.